TY - JOUR
T1 - Islet inflammation and ductal proliferation may be linked to increased pancreatitis risk in type 2 diabetes
AU - Schludi, Belinda
AU - Moin, Abu Saleh Md
AU - Montemurro, Chiara
AU - Gurlo, Tatyana
AU - Matveyenko, Aleksey V.
AU - Kirakossian, David
AU - Dawson, David W.
AU - Dry, Sarah M.
AU - Butler, Peter C.
AU - Butler, Alexandra E.
N1 - Funding Information:
We appreciate the technical assistance of Bonnie Yeh and Rosibel Hernandez and the editorial assistance of Bonnie Lui, all from the Hillblom Islet Research Center at UCLA. We appreciate the services of the Translational Pathology Core Laboratory (TPCL) at UCLA for whole-slide scanning. This research was performed with the support of the nPOD, a collaborative T1D research project sponsored by the Juvenile Diabetes Research Foundation International. Organ Procurement Organizations (OPO) partnering with nPOD to provide research resources are listed at www.jdrfnpod.org/our-partners.php. These studies were funded by the NIH/NIDDK (DK077967), the Larry Hillblom Foundation (2014-D-001-NET), and the Juvenile Diabetes Research Foundation.
Publisher Copyright:
© 2017 American Society for Clinical Investigation. All rights reserved.
PY - 2017/7/6
Y1 - 2017/7/6
N2 - Pancreatitis is more frequent in type 2 diabetes mellitus (T2DM), although the underlying cause is unknown. We tested the hypothesis that ongoing β cell stress and apoptosis in T2DM induces ductal tree proliferation, particularly the pancreatic duct gland (PDG) compartment, and thus potentially obstructs exocrine outflow, a well-established cause of pancreatitis. PDG replication was increased 2-fold in human pancreas from individuals with T2DM, and was associated with increased pancreatic intraepithelial neoplasia (PanIN), lesions associated with pancreatic inflammation and with the potential to obstruct pancreatic outflow. Increased PDG replication in the prediabetic human-IAPP-transgenic (HIP) rat model of T2DM was concordant with increased β cell stress but preceded metabolic derangement. Moreover, the most abundantly expressed chemokines released by the islets in response to β cell stress in T2DM, CXCL1, -4, and -10, induced proliferation in human pancreatic ductal epithelium. Also, the diabetes medications reported as potential modifiers for the risk of pancreatitis in T2DM modulated PDG proliferation accordingly. We conclude that chronic stimulation and proliferation of the PDG compartment in response to islet inflammation in T2DM is a potentially novel mechanism that serves as a link to the increased risk for pancreatitis in T2DM and may potentially be modified by currently available diabetes therapy.
AB - Pancreatitis is more frequent in type 2 diabetes mellitus (T2DM), although the underlying cause is unknown. We tested the hypothesis that ongoing β cell stress and apoptosis in T2DM induces ductal tree proliferation, particularly the pancreatic duct gland (PDG) compartment, and thus potentially obstructs exocrine outflow, a well-established cause of pancreatitis. PDG replication was increased 2-fold in human pancreas from individuals with T2DM, and was associated with increased pancreatic intraepithelial neoplasia (PanIN), lesions associated with pancreatic inflammation and with the potential to obstruct pancreatic outflow. Increased PDG replication in the prediabetic human-IAPP-transgenic (HIP) rat model of T2DM was concordant with increased β cell stress but preceded metabolic derangement. Moreover, the most abundantly expressed chemokines released by the islets in response to β cell stress in T2DM, CXCL1, -4, and -10, induced proliferation in human pancreatic ductal epithelium. Also, the diabetes medications reported as potential modifiers for the risk of pancreatitis in T2DM modulated PDG proliferation accordingly. We conclude that chronic stimulation and proliferation of the PDG compartment in response to islet inflammation in T2DM is a potentially novel mechanism that serves as a link to the increased risk for pancreatitis in T2DM and may potentially be modified by currently available diabetes therapy.
UR - http://www.scopus.com/inward/record.url?scp=85048673500&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048673500&partnerID=8YFLogxK
U2 - 10.1172/jci.insight.92282
DO - 10.1172/jci.insight.92282
M3 - Article
C2 - 28679961
AN - SCOPUS:85048673500
SN - 2379-3708
VL - 2
JO - JCI insight
JF - JCI insight
IS - 13
M1 - e92282
ER -